It should come as no surprise to see insider selling at current market levels, and we expect the pace to continue through the rest of the summer and into the fall.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
These are clearly not the most exciting companies on Wall Street, but if you are an investor concerned about where to own shares, the United States remains the clear-cut winner.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
With so much of the sovereign debt around the world with negative yields, and the rest just barely over the breakeven level, many people are looking far and wide for any sort of reasonable…
If the Jefferies strategist is right, and history repeats itself, these four top stock should all do outstanding over the next three months.
Every once in a while, investors get the kind of gift that pays off in an outstanding way because others investors shoot first and ask questions later.
A new report from Wedbush focuses on upcoming catalysts for biotech stocks in the firm's coverage universe. These four have monster potential upside to the posted price targets.
In a new Baird research report, while the analysts are positive on alternative energy as a whole, they are very selective on the stocks they like.
With major production cuts and rig counts well below two years ago, now may be a good time to nibble at some of the top oil stocks that have been hammered over the past…
A top-notch Jefferies economist believes the rise in populism is the most important issue the markets face today, and that the biggest impact from a Trump win would be a weaker U.S. dollar.
The general consensus is that telecom is overbought and a crowded trade, but Merrill Lynch thinks that from a yield perspective it still makes sense for investors looking for dividends.
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
This week the analysts at Jefferies are focusing their top growth stock picks on some very large and liquid stocks, and two of them are technology leaders that posted outstanding second-quarter earnings.
The tsunami of insider selling that was kicked off when the market broke through to all-time highs slowed down a little last week, but there were still some pretty big waves.
Some backup in the markets and some steep sell-offs in individual companies sure did open the door for insider buyers this past week.
These three biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the last year and are offering aggressive accounts the best entry points in…
These four top stocks that pay at least a 3% dividend also offer investors outstanding entry points at current levels.
Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
The biggest companies are often the safest to buy, and with the market still right at all-time highs, these liquid, large cap leaders make good sense now.
